[TENAGA] YoY Annualized Quarter Result on 31-Aug-2012 [#4]

Announcement Date
31-Oct-2012
Admission Sponsor
-
Sponsor
-
Financial Year
31-Aug-2012
Quarter
31-Aug-2012 [#4]
Profit Trend
QoQ- -1.24%
YoY- 356.86%
View:
Show?
Annualized Quarter Result
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
Revenue 43,286,800 42,792,400 37,130,700 35,848,400 32,241,200 30,317,400 28,785,600 7.03%
PBT 7,133,700 7,114,700 5,925,100 5,821,100 1,156,700 4,019,400 1,543,100 29.05%
Tax -1,072,800 -687,900 -542,300 -1,402,000 -192,200 -823,200 -690,100 7.62%
NP 6,060,900 6,426,800 5,382,800 4,419,100 964,500 3,196,200 853,000 38.63%
-
NP to SH 6,118,400 6,467,000 5,356,200 4,410,500 965,400 3,200,800 917,900 37.16%
-
Tax Rate 15.04% 9.67% 9.15% 24.08% 16.62% 20.48% 44.72% -
Total Cost 37,225,900 36,365,600 31,747,900 31,429,300 31,276,700 27,121,200 27,932,600 4.90%
-
Net Worth 47,210,047 43,224,325 37,215,604 34,659,433 31,976,724 30,073,719 25,985,496 10.45%
Dividend
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
Div 1,636,690 1,636,643 1,393,008 1,097,758 245,387 1,128,958 770,117 13.38%
Div Payout % 26.75% 25.31% 26.01% 24.89% 25.42% 35.27% 83.90% -
Equity
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
Net Worth 47,210,047 43,224,325 37,215,604 34,659,433 31,976,724 30,073,719 25,985,496 10.45%
NOSH 5,643,759 5,643,599 5,572,032 5,464,202 5,453,056 4,342,148 4,333,805 4.49%
Ratio Analysis
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
NP Margin 14.00% 15.02% 14.50% 12.33% 2.99% 10.54% 2.96% -
ROE 12.96% 14.96% 14.39% 12.73% 3.02% 10.64% 3.53% -
Per Share
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
RPS 766.99 758.25 666.38 656.06 591.25 698.21 664.21 2.42%
EPS 108.41 114.59 96.13 80.71 17.71 58.92 21.18 31.26%
DPS 29.00 29.00 25.00 20.09 4.50 26.00 17.77 8.50%
NAPS 8.365 7.659 6.679 6.343 5.864 6.926 5.996 5.70%
Adjusted Per Share Value based on latest NOSH - 5,465,834
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
RPS 744.66 736.16 638.76 616.70 554.64 521.55 495.20 7.03%
EPS 105.25 111.25 92.14 75.87 16.61 55.06 15.79 37.16%
DPS 28.16 28.16 23.96 18.88 4.22 19.42 13.25 13.38%
NAPS 8.1215 7.4359 6.4022 5.9625 5.5009 5.1736 4.4703 10.45%
Price Multiplier on Financial Quarter End Date
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
Date 28/08/15 29/08/14 30/08/13 30/08/12 29/08/11 30/08/10 28/08/09 -
Price 11.18 12.38 8.73 6.84 5.25 5.67 5.13 -
P/RPS 1.46 1.63 1.31 1.04 0.89 0.81 0.77 11.24%
P/EPS 10.31 10.80 9.08 8.47 29.65 7.69 24.22 -13.26%
EY 9.70 9.26 11.01 11.80 3.37 13.00 4.13 15.28%
DY 2.59 2.34 2.86 2.94 0.86 4.59 3.46 -4.71%
P/NAPS 1.34 1.62 1.31 1.08 0.90 0.82 0.86 7.66%
Price Multiplier on Announcement Date
31/08/15 31/08/14 31/08/13 31/08/12 31/08/11 31/08/10 31/08/09 CAGR
Date 29/10/15 31/10/14 31/10/13 31/10/12 28/10/11 28/10/10 26/10/09 -
Price 12.66 13.36 9.43 6.95 5.86 5.68 5.43 -
P/RPS 1.65 1.76 1.42 1.06 0.99 0.81 0.82 12.35%
P/EPS 11.68 11.66 9.81 8.61 33.10 7.71 25.64 -12.27%
EY 8.56 8.58 10.19 11.61 3.02 12.98 3.90 13.99%
DY 2.29 2.17 2.65 2.89 0.77 4.58 3.27 -5.76%
P/NAPS 1.51 1.74 1.41 1.10 1.00 0.82 0.91 8.80%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment